For this protein to be excreted in levels high enough to act as an antitumour agent, ways must be developed which would either allow increased TNF-α production at the tumour site or utilized the synergistic effect of interleukin-2 and TNF-α [42, 43]. This evidence concerns the gene TNF and neoplasm.